Back to top
more

REGENXBIO (RGNX)

(Delayed Data from NSDQ)

$9.43 USD

9.43
668,980

+0.51 (5.72%)

Updated Nov 6, 2024 03:59 PM ET

After-Market: $9.10 -0.33 (-3.50%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value C Growth D Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 38% (95 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

REGENXBIO (RGNX) Provides Update on RGX-314 & Begins New Program

by Zacks Equity Research

REGENXBIO (RGNX) provided an update on the RGX-314 programs. Further, the company made an announcement of a new program, RGX-202, for the treatment of Duchenne Muscular Dystrophy

The Zacks Analyst Blog Highlights: BioMarin Pharmaceutical, uniQure, REGENXBIO and Deciphera Pharmaceuticals

by Zacks Equity Research

The Zacks Analyst Blog Highlights: BioMarin Pharmaceutical, uniQure, REGENXBIO and Deciphera Pharmaceuticals

4 Biotechs That Could Be Potential Acquisition Targets in 2021

by Zacks Equity Research

We discuss a few attractive biotech companies that flaunt solid product portfolios, deep pipelines and lucrative valuations to emerge as likely acquisition targets in 2021.

Regenxbio (RGNX) Surpasses Q3 Earnings and Revenue Estimates

by Zacks Equity Research

Regenxbio (RGNX) delivered earnings and revenue surprises of 125.84% and 284.87%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

What's in the Cards for Enlivex (ENLV) This Earnings Season?

by Zacks Equity Research

Investors will be keen on pipeline updates when Enlivex Therapeutics (ENLV) reports results for the three months ending Sep 30, 2020.

Is a Disappointment in Store for Tilray's (TLRY) Q3 Earnings?

by Zacks Equity Research

Investors will focus on revenue growth and other pipeline updates, when Tilray (TLRY) reports third-quarter 2020 results.

Neurocrine (NBIX) to Report Q3 Earnings: What's in Store?

by Zacks Equity Research

Investors are expected to focus on Neurocrine's (NBIX) updates on Ingrezza outlook and its pipeline candidates' progress when it reports third-quarter results.

Is a Disappointment in Store for Zosano (ZSAN) Q3 Earnings?

by Zacks Equity Research

Investors will be keen on updates on Qtrypta when Zosano (ZSAN) reports Q3 results.

Mylan (MYL) to Report Q3 Earnings: Is a Beat in the Cards?

by Zacks Equity Research

Investors will look forward to regular top and bottom-line numbers and updates on the merger with Upjohn, when Mylan (MYL) reports Q3 results.

Is a Beat in the Cards for Bristol-Myers' (BMY) Q3 Earnings?

by Zacks Equity Research

Investors will focus on regular top and bottom-line numbers along with key pipeline updates when Bristol-Myers (BMY) reports third-quarter 2020 results.

What's in the Cards for Regeneron's (REGN) Q3 Earnings?

by Zacks Equity Research

Investors will focus on the performance of Eylea and Dupixent along with other pipeline updates when Regeneron (REGN) reports third-quarter 2020 results.

Incyte (INCY) to Post Q3 Earnings: Will Jakafi Drive Results?

by Zacks Equity Research

Investors will focus on regular top and bottom-line numbers along with pipeline updates, when Incyte (INCY) reports third-quarter 2020 results.

What's in the Cards for Cassava (SAVA) This Earnings Season?

by Zacks Equity Research

Investors will be keen on updates from the recent study on its lead candidate, sumifilam, when Cassava (SAVA) reports Q3 results.

Regenxbio (RGNX) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

Regenxbio (RGNX) delivered earnings and revenue surprises of -2.25% and -14.56%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Regenxbio (RGNX) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Regenxbio (RGNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Regenxbio (RGNX) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

by Zacks Equity Research

Regenxbio (RGNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Regenxbio (RGNX) Reports Q4 Loss, Lags Revenue Estimates

by Zacks Equity Research

Regenxbio (RGNX) delivered earnings and revenue surprises of -80.00% and -70.34%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Applied Genetic Stock Up on Favorable Eye Therapy Study Data

by Zacks Equity Research

Applied Genetic's (AGTC) gene therapy candidate shows promise in an early-stage study to treat X-linked retinitis pigmentosa, a rare eye disorder.

Regenxbio (RGNX) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Regenxbio (RGNX) delivered earnings and revenue surprises of -3.30% and 97.18%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Ultragenyx's (RARE) NDA for LC-FAOD Drug Accepted by FDA

by Zacks Equity Research

Ultragenyx (RARE) announces FDA's acceptance of the NDA for UX007 for the treatment of LC-FAOD.

Ekta Bagri headshot

Wet AMD Space in Focus: New Drug Approvals & Key Advancements

by Ekta Bagri

The FDA approval of Novartis' Beovu for wet AMD brings this space to focus. Let us assess the recent key developments in the area.

Ultragenyx Gets FDA Approval for Label Expansion of Crysvita

by Zacks Equity Research

Ultragenyx (RARE) and partner Kyowa Kirin get FDA approval for the label expansion of Crysvita in pediatric patients with X-linked hypophosphatemia.

REGENXBIO (RGNX) Catches Eye: Stock Jumps 5.8%

by Zacks Equity Research

REGENXBIO (RGNX) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.

Ultragenyx-GeneTx Get Orphan Drug Status for GTX-102 From FDA

by Zacks Equity Research

The FDA grants Orphan Drug and Rare Pediatric Disease designations to Ultragenyx (RARE) and partner GeneTx Biotherapeutics' GTX-102 for the treatment of Angelman Syndrome.

Ultragenyx (RARE) Focuses on Pipeline Amid Low Revenues

by Zacks Equity Research

Ultragenyx (RARE) focuses on the development of pipeline candidates. Being a new commercial company with lower revenues, development or regulatory setbacks could result in higher operating expenses.